ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / RTSN
MIST (33) TNXP (25) GNLX (26) PLYX (27) ⌘ Pro Terminal →

Retension Pharmaceuticals Inc. (RTSN) — RQD Stock Rating Cockpit

$11.30 -0.53% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.27

Retension Pharmaceuticals Inc. (RTSN) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $89.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RTSN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RTSN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Retension Pharmaceuticals Inc. (NASDAQ: RTSN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $11.30 (-0.53% 1D, market cap $89.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, RTSN ranks #254 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RTSN compare to MIST and TNXP in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RTSN carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MIST (Milestone Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $89.8M) and TNXP (Tonix Pharmaceuticals Holding Corp.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $88.3M). Among the 5-stock peer group, RTSN leads on earnings multiple (N/A) while MIST leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RTSN?
▼

For Retension Pharmaceuticals Inc. (RTSN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #254 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $11.27 (-0.29%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510051
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk C
Cash (12)Whales (5)SEC (13)Macro (12)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-3.2% Base Target
$20 Bull$11 Base$9 Bear
📬 FREE RTSN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RTSN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (51/100 Composite)
🔍 WHY RTSN SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($2.5M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
59
Grade C$11.63+39.1% Next Q
Q2 (-2Q)
56
Grade C$16.18-16.4% Next Q
Q3 (-1Q)
54
Grade C-$13.52-16.4% Next Q
Current
51
Grade D$11.30-1.3% Hist 90D α
Trajectory: C (59) → D (51)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RTSN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RTSN currently carries a cautious 51/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.66) and Max Pain ($11.87) forces dealer call-delta covering toward $19.57.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RTSN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RTSN Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 51%NO 49%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
55.430 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE18% OF RANGE
L: $10$11.30H: $19
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

Quant Analyst Panel Split (Battleground) on RTSN

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (43)

14/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like RTSN
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RTSN)

  • ✓Walkthrough of RTSN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RTSN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +7.31%📐 HORIZONTAL RANGE
2026-11-03O $11.07H $12.25L $11.07C $11.30VOL 81.5K
SUP: $9.78SMA50: $13.13
$19.27$16.66$14.06$11.46$8.85SUP $9.78$11.302026-10-092026-10-152026-10-212026-10-272026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RTSN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RTSN Butterfly Map → + Track RTSN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RTSN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RTSN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RTSN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RTSN)

Health Care Rank #254 of 1015 ⚔️ MIST vs RTSN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RTSN vs. MIST, TNXP, GNLX, PLYX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Retension Pharmaceuticals Inc. (RTSN) ranks #254 by composite RQD confidence (51/100, grade D) and #666 by equity capitalization ($89.1M). Within this direct 5-issuer industry benchmark cohort, RTSN leads on earnings valuation at N/A trailing P/E, while MIST leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RTSN currently leads its immediate peer cohort in composite quantitative strength at 51/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RTSN ACTIVE
Retension Pharmaceuticals Inc.
D 51/100 — — — -0.53% $89.1M Benchmark Subject
MIST
Milestone Pharmaceuticals Inc.
E 33/100 — — -35.0% -1.22% $89.8M /mist-vs-rtsn →
TNXP
Tonix Pharmaceuticals Holding Corp.
E 25/100 — 49.3% -35.0% +0.98% $88.3M /tnxp-vs-rtsn →
GNLX
Genelux Corporation
E 26/100 — — -35.0% -3.85% $90.5M /gnlx-vs-rtsn →
PLYX
Polaryx Therapeutics Inc.
E 27/100 — — -35.0% 0.00% $87.2M /plyx-vs-rtsn →

2. RTSN Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Retension Pharmaceuticals Inc. (RTSN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $89.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. RTSN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RTSN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Retension Pharmaceuticals Inc. (NASDAQ: RTSN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $11.30 (-0.53% 1D, market cap $89.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, RTSN ranks #254 in composite RQD confidence.

How does RTSN compare to MIST and TNXP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RTSN carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MIST (Milestone Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $89.8M) and TNXP (Tonix Pharmaceuticals Holding Corp.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $88.3M). Among the 5-stock peer group, RTSN leads on earnings multiple (N/A) while MIST leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RTSN?

For Retension Pharmaceuticals Inc. (RTSN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #254 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RTSN trading relative to its 50-day, 200-day, and 52-week technical levels?

RTSN last traded at $11.30 (-0.53% on volume of 71,290 shares), positioning the stock -10.74% below its 50-day simple moving average ($12.66) and -8.94% below its 200-day simple moving average ($12.41). Across its 52-week range of $9.66 to $18.64, RTSN sits at the 18.3% percentile with a 14-day RSI of 55.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($9.89 to $12.71).

Direct Sub-Reports: RTSN RQD Cockpit RTSN 12M Forecast RTSN Earnings & Move RTSN Dividends & DRIP RTSN Insiders & 13F RTSN Whale Options RTSN Profit Sankey RTSN News & Why
ROARABLE RATING BRIEF • RQD 51/100 (D) ✓ SEC XBRL & RQD VERIFIED

RTSN — Retension Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Retension Pharmaceuticals Inc. (RTSN) earns a live Roarable RQD composite score of 51/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $11.30 (-0.53% 1D, market capitalization $89.1M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Retension Pharmaceuticals Inc. (RTSN) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry,. The profile reports a market capitalization of $0.1B. Per the market data, the company's gross, operating, and net margins are each reported as 0%.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 51/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $9.66 – $18.64 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlation data are therefore — Investors should note that the absence of mapped dependencies means second-order ripple effects cannot be traced from the source data.

  • Key Question #1: Can RTSN sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $18.64 52-week high?
  • Key Question #3: How sensitive is RTSN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

RTSN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Retension Pharmaceuticals Inc. (RTSN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RTSN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RTSN Bull vs. Bear Conversation Board — What's Your Call at $11.30?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RTSN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RTSN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $14.43 (+27.0%)
📌 Pinned Debate

Balance-sheet forensics are the strongest pillar at 13 of 20, with an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5.

Balance-sheet forensics are the strongest pillar at 13 of 20, with an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5.. When you look under the hood at RTSN, Fundamental Cash Engine is 12/20 with 0.0% gross margins and 0.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (5/20) has been quietly accumulating below $18.64. My 12M target is $14.43.

VolSurface_Trader 🐂 BULL

Both sides have a point here — RTSN's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $9.20 (-19.0%)
Spot @ $11.36

Institutional whale/13F flow scores only 4 of 20 and fundamental cash generation reports 0% ROIC and 0% FCF yield, with a Sell verdict

Here is the bear case nobody on the bull side wants to address on RTSN: Institutional whale/13F flow scores only 4 of 20 and fundamental cash generation reports 0% ROIC and 0% FCF yield, with a Sell verdict and distribution warning.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE